Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. - Wikidata - wikimedia - TriplyDB

Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties.

Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties.

http://www.wikidata.org/entity/Q34778803

about

Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders In vivo evaluation of alpha7 nicotinic acetylcholine receptor agonists [11C]A-582941 and [11C]A-844606 in mice and conscious monkeys Chemical chaperones exceed the chaperone effects of RIC-3 in promoting assembly of functional α7 AChRs Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model.Design, synthesis, and pharmacological characterization of novel spirocyclic quinuclidinyl-Δ2-isoxazoline derivatives as potent and selective agonists of α7 nicotinic acetylcholine receptors.Decreasing nicotinic receptor activity and the spatial learning impairment caused by the NMDA glutamate antagonist dizocilpine in rats.Brain imaging of nicotinic receptors in Alzheimer's disease.α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease.Pharmacological enhancement of memory and executive functioning in laboratory animals.The effects of aging vs. α7 nAChR subunit deficiency on the mouse brain transcriptome: aging beats the deficiency.Cancer 'survivor-care': I. the α7 nAChR as potential target for chemotherapy-related cognitive impairment.The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.Pro-cognitive activity in rats of 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic acetylcholine receptor Epinephrine and glucose modulate training-related CREB phosphorylation in old rats: relationships to age-related memory impairments.Occupancy of α7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [(11)C]CHIBA-1001 in Healthy Human Subjects Nicotinic receptors in neurodegeneration.Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings.Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia.The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors.Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.Radioligand binding characterization of neuronal nicotinic acetylcholine receptors.Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.Type I and II positive allosteric modulators differentially modulate agonist-induced up-regulation of α7 nicotinic acetylcholine receptors.Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.Effects of α7 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis.

P2860

Q26765419-2B0EB43F-9ACB-4532-84C2-DBFD4569D617 Q28472724-39BCDC25-6241-4E60-A537-DAFFC749745E Q28486758-9415409A-B61F-42D6-9BBC-B11F828E8864 Q28595059-511E9F4B-8848-4F05-8B6C-926D91AD2475 Q30362464-E1E2274B-49FD-45FE-9C3A-0BE9B08C9099 Q30478035-F8D973C4-2B87-4B72-8871-4BFE6B5DB76A Q30577199-6D08EB0C-DBAE-4C35-BF7A-DA9F3346F9A8 Q34167942-2F33D368-8236-4C87-9077-F81D2D3ABE02 Q34287941-8A3D01BF-22E8-4453-AEFF-88C61AEAE0CD Q34496928-AE8B11FB-7352-44BC-B672-EDC62F4FF355 Q34501147-9E595AEA-A7D4-4691-806A-BB6282A62CA2 Q34661221-101647C1-9508-41E9-B5C6-15F1EE24F39B Q34714815-F581C7D7-1C50-4183-AE07-579E5BA6B5D3 Q35646004-39494AC4-7AF2-4FDD-8C7F-42F0069EB642 Q36088364-74E02726-2113-40AD-8986-5D135191B36B Q36394997-D82A7CF8-EACA-4EE3-872D-AA49E9E54FF4 Q36569516-01AF1234-3FF1-4AA4-A418-E61F8817112A Q36600684-607739E8-31E1-478B-A7EE-5C31C44AFD85 Q36828916-68A4E020-EB6F-490F-881F-4756703A3C2D Q37826637-2CA30A7C-4657-4B65-8579-AC802346E27E Q38066550-86FCFD88-018D-4E0A-BB63-F78CC11615D9 Q38560778-CD1631F3-1702-44A2-A3BD-1B0949B3DA40 Q39785082-B76B1D99-7A14-4E7B-BF62-1601D19691AD Q41890142-F1892211-3F61-41BF-922E-BFB592E2AA68 Q42721778-8BCF6E95-63EF-49FA-B518-631F51D1AD65 Q44599683-13C4BDA7-CE2F-4E45-9D6C-4D76C3FA607D Q45838952-E5A34AC2-4BB9-4883-98AA-17AA12CB4E75 Q48840774-7F832775-5A80-40A6-AE44-0E40B3D4910C Q53400234-F1EEAF9E-5564-4639-8211-BAB7664845C5

P2860

Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties.

http://www.wikidata.org/entity/Q34778803

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Preclinical characterization o ...... ognition-enhancing properties.

@ast

Preclinical characterization o ...... ognition-enhancing properties.

@en

Preclinical characterization o ...... ognition-enhancing properties.

@nl

type

label

Preclinical characterization o ...... ognition-enhancing properties.

@ast

Preclinical characterization o ...... ognition-enhancing properties.

@en

Preclinical characterization o ...... ognition-enhancing properties.

@nl

prefLabel

Preclinical characterization o ...... ognition-enhancing properties.

@ast

Preclinical characterization o ...... ognition-enhancing properties.

@en

Preclinical characterization o ...... ognition-enhancing properties.

@nl

P1433

Q34778803-9E91F7AF-C9A4-448E-9411-22F252512059

P1476

Q34778803-DC60E5C6-9150-4AA2-A6DE-ABF6971CA6E5

P2093

Q34778803-04528D45-27E4-42F5-9287-1BC2AAB694B9

Q34778803-0FAC1EA9-4EFD-4F07-AF8C-C3B598156F1D

Q34778803-17674428-81DA-4612-BFED-0DA4807F4488

Q34778803-17FB8242-2B5B-45FA-BAE4-70C1F300DBA3

Q34778803-195763C4-B520-445C-ACB5-2D3AC3D457ED

Q34778803-1C1641B2-6875-43AB-A39E-AFC5DCBB8F6C

Q34778803-1FCA73FD-7B06-4B13-98F5-035D01553126

Q34778803-2873DD81-AE08-4613-BF39-4A6AD6742EB8

Q34778803-32D540EC-E1D6-4271-BB45-2A6828DD70DE

Q34778803-35D374B1-3B60-4C65-A10F-5E3FC3BC306D

P2860

Q34778803-005A3E85-14F7-48F8-9CF1-E716D4AE36DD

Q34778803-00864212-681A-4504-8349-EAA950A4E5BB

Q34778803-00B5DC70-6738-45DE-9B93-8CFBCFB8B35D

Q34778803-0558D3B3-4501-4321-9362-350866944CCC

Q34778803-11DB2328-3D74-4F36-B7C4-6E8D965EBF66

Q34778803-1268A6AF-A8C1-4669-8B8E-BB77E5F8E166

Q34778803-16948582-C1D2-404F-B9FE-EED62E068F3B

Q34778803-1811AC0E-6704-4F33-ACF0-66FE0087E8C9

Q34778803-1B75C290-4232-4B06-A41C-2A99579D4977

Q34778803-1C33FE7B-E55E-4ED7-92E1-23EA3F73C011

P304

Q34778803-6ED97CDA-99C7-458D-9928-0E308DC7C072

P31

Q34778803-446D946F-B93F-489C-893E-424D2EE3A980

P356

Q34778803-1FB259FC-FF3B-4536-B0E9-6DDC1080683D

P433

Q34778803-C217D24E-D097-4B51-910D-5EF2397FA02F

P478

Q34778803-A188A5C2-E9DC-4040-9F74-C1BC9EC2CBC3

P577

Q34778803-C5FC1030-637A-446D-A059-427B66BD1608

P698

Q34778803-E85BE627-3EC0-490F-BED4-1DED28DF1923

P356

J.1755-5949.2008.00037.X

P1433

CNS Neuroscience & Therapeutics

P1476

Preclinical characterization o ...... ognition-enhancing properties.

@en

P2093

Angela L Molesky

http://www.w3.org/2001/XMLSchema#string

Arthur L Nikkel

http://www.w3.org/2001/XMLSchema#string

Clark A Briggs

http://www.w3.org/2001/XMLSchema#string

Dagmar Bury

http://www.w3.org/2001/XMLSchema#string

David J Anderson

http://www.w3.org/2001/XMLSchema#string

Devalina Law

http://www.w3.org/2001/XMLSchema#string

Earl J Gubbins

http://www.w3.org/2001/XMLSchema#string

Eric A Blomme

http://www.w3.org/2001/XMLSchema#string

Eva Spies

http://www.w3.org/2001/XMLSchema#string

Gerard B Fox

http://www.w3.org/2001/XMLSchema#string

P2860

Interaction of tobacco-specific toxicants with the neuronal alpha(7) nicotinic acetylcholine receptor and its associated mitogenic signal transduction pathway: potential role in lung carcinogenesis and pediatric lung disorders

Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda

Nicotine promotes cell proliferation via alpha7-nicotinic acetylcholine receptor and catecholamine-synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells

Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells

Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer

The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist

Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists

Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7)

Neuronal nicotinic receptors: from structure to pathology

Role of neuronal nicotinic receptors in the effects of nicotine and ethanol on contextual fear conditioning

P304

65-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1755-5949.2008.00037.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18482100

http://www.w3.org/2001/XMLSchema#string